New class of oral treatment for overactive bladder

Post Hoc Analysis of a Phase III study into the treatment benefits Betmiga^� (mirabegron), the first new case of oral treatment for overactive bladder for 30 years, has been published in the journal BMC Urology.

The randomised, double-blinded, placebo- and active-controlled Phase III, EU/Australian investigated the efficacy and tolerably in both treatment-na�ve patients and those who had been previously discontinued treatment with an antimuscarinic. Results demonstrated that mirabegron showed improved frequency of incontinence and number of mucturations per 24 hours compared with both placebo and antimuscarinic therapy¹. In addition tolerability was good and treatment-emergent events were low^2,3,4, common side effect dry mouth occurred with the same incidence in the placebo group and was three fold lower than in those patients receiving antimuscarinic treatments².

References

1. Khullar V, Cambronero J, Angulo JC et al. BMC Urology 2013; 13:45 doi:10.1186/1471-2490-13-45
2. Khullar V., Amarenco G., Angulo J.C., et al. Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder: results from a randomized European-Australian phase 3 trial. Eur Urol. 2013 Feb; 63(2):283-95
3. Chapple CR., Kaplan SK., Mitcheson D., et al. Randomised, doubleblind, placebo-controlled Phase III study to assess the efficacy and safety of mirabegron, a β3-adrenoceptor agonist, in overactive bladder. Eur Urol 2013 Feb; 63(2):296-305
4. Van Kerrebroeck P, Barkin J, Castro-Diaz D et al. Randomised, double-blind, placebo-controlled Phase III study to assess the efficacy and safety of mirabegron 25 mg and 50 mg once daily in overactive bladder (OAB). Presented at ICS 2012